I founded Prescient Healthcare Group in 2007 and served as CEO until 2022, during which Prescient became a leading biopharma product and portfolio strategy firm. We grew to ~450 colleagues across the US, Europe and Asia; partnered with ~70 biopharma organisations, supporting 250+ assets and brands across drug development and commercialisation; and completed two private equity transactions and a tuck-in acquisition. Baird Capital backed Prescient for three and a half years before Prescient moved to Bridgepoint in 2021, generating a 5.0x MOIC and a 59% IRR.
I now support JMAN Group (Baird-backed) as a Non-Executive Director, act as an operating advisor to Baird Capital with a focus on pharma services and remain an active healthcare investor.